We are thrilled to announce our upsized Series C financing today! With the $200 million in proceeds, we are advancing obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb to inhibit B-lineage cell activity, for patients with #autoimmunediseases. Thanks to our exceptional investors and #zenasbio team for supporting our progress as we aim to become a global leader in the development and commercialization of I&I therapies. Read the press release: https://lnkd.in/eaB8cg3D
Zenas BioPharma
Biotechnology Research
Waltham, MA 4,355 followers
Bringing innovative immune-based therapies to the World
About us
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies for patients around the world. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com.
- Website
-
https://zenasbio.com/
External link for Zenas BioPharma
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Waltham, MA
- Type
- Privately Held
Locations
-
Primary
Get directions
1000 Winter St
Suite 1200
Waltham, MA 02451, US
-
Get directions
1515 West Nanjing Road
Level 7, Tower 2, Jing'an Kerry Center
Jing'an District, Shanghai 200041, CN
Employees at Zenas BioPharma
Updates
-
A round of applause for this group of recently promoted team members! We’re inspired by your efforts and are looking forward to seeing your next achievements.#zenasbio #promotions
-
We’re thrilled to welcome Patricia Allen to our Board of Directors! Patty’s expertise in finance coupled with her extensive leadership experience will further strengthen our board, as we continue to advance our immunology-based therapies for patients in need. Read more about it here: https://bit.ly/3ToF5Zo
-
During this holiday season, Zenas gave back to the Waltham, MA community by sponsoring two families in need by purchasing presents for their holiday celebrations. We wish you and your family happy holidays, and we look forward to an exciting 2024! #zenas #happyholidays
-
Zenas is thrilled to welcome Jen Fox as Chief Business Officer and Chief Financial Officer and Dr. Tanya Fischer as Head of R&D and Chief Medical Officer. Tanya and Jen further strengthen our deeply experienced leadership team as we advance our lead program, obexelimab, in late-stage clinical trials for multiple potential I&I indications. #Zenas # TRUEInnovation.
Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
globenewswire.com
-
This week, some of our team members visited Cradles to Crayons to volunteer their time by cleaning shoes to be donated to children in need. Thanks to our team for taking the time and helping out the community! #zenasbio #volunteer
-
-
Great news for patients living with IgG4-RD!
It is with great excitement that we announce the launch of IgG4ward!, the first and only organization solely dedicated to supporting those living with IgG4-RD, a chronic and debilitating autoimmune condition that affects approximately 40,000 patients in the United States and hundreds of thousands globally. Founded by Dr. John Stone MD, MPH, Professor of Medicine at Harvard Medical School and the Edward A. Fox Chair in Medicine at the Massachusetts General Hospital in Boston, IgG4ward! is the first and only organization solely dedicated to supporting those living with IgG4-RD. “Our plan is to create synergy within the community of IgG4-RD patients, their care partners, and clinicians to tackle every aspect of this disease. The rapid momentum we have generated with IgG4ward! demonstrates the large unmet need we are addressing,” shares Dr. Stone. In preparation of IgG4ward!'s official launch in November of 2023, we encourage you to learn more about the foundation here: https://shorturl.at/hjEQ8 #raredisease #rarediseaseawareness #medicalresearch
Home | IgG4ward!
igg4ward.org
-
We are thrilled to announce a strategic collaboration with Bristol Myers Squibb (BMS) to develop and commercialize obexelimab to treat rare #autoimmunedisease diseases such as #IgG4-related disease, in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. BMS will make an equity investment in Zenas in connection with the collaboration. We are proud to partner with BMS in support of our vision to bring innovative immunology-based therapies to patients around the world. Read the full press release here: https://bit.ly/44IZtXA
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
globenewswire.com
-
We are very excited to share the publication of the results of the obexelimab Phase 2 study in patients with IgG4-related disease (RD) in The Lancet Rheumatology! The study showed that obexelimab produced rapid, strong, and sustained clinical improvement, including complete remission (IgG4-RD Responder Index score of 0), in most patients with active IgG4-RD. Based on the results of this study, a Phase 3 study is ongoing to further investigate the efficacy and safety of obexelimab administered as a subcutaneous injection. The article can be read here: https://lnkd.in/eJB9uE3z Special thanks to the team and all of our collaborators for their hard work and dedication! #lancet , #rheumatology , #IgG4-RD
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial
sciencedirect.com